Humana Inc. (NYSE:HUM) Shares Acquired by M&T Bank Corp

M&T Bank Corp lifted its position in shares of Humana Inc. (NYSE:HUM) by 9.8% in the first quarter, HoldingsChannel reports. The institutional investor owned 9,265 shares of the insurance provider’s stock after purchasing an additional 828 shares during the period. M&T Bank Corp’s holdings in Humana were worth $2,451,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in HUM. Riverview Trust Co acquired a new stake in shares of Humana during the 1st quarter worth $34,000. Garde Capital Inc. purchased a new stake in shares of Humana in the first quarter worth about $36,000. Transce3nd LLC acquired a new stake in shares of Humana in the fourth quarter valued at about $38,000. Whipplewood Advisors LLC grew its stake in shares of Humana by 639.1% in the first quarter. Whipplewood Advisors LLC now owns 170 shares of the insurance provider’s stock valued at $45,000 after buying an additional 147 shares in the last quarter. Finally, Colonial Trust Advisors raised its holdings in shares of Humana by 4,500.0% during the 4th quarter. Colonial Trust Advisors now owns 184 shares of the insurance provider’s stock valued at $47,000 after buying an additional 180 shares during the period. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Humana Stock Down 0.8%

NYSE:HUM opened at $230.38 on Friday. The company has a market capitalization of $27.80 billion, a price-to-earnings ratio of 16.29, a price-to-earnings-growth ratio of 1.75 and a beta of 0.44. Humana Inc. has a one year low of $212.45 and a one year high of $406.46. The stock has a 50-day simple moving average of $237.78 and a 200 day simple moving average of $258.31. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.91 and a current ratio of 1.91.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, April 30th. The insurance provider reported $11.58 EPS for the quarter, topping analysts’ consensus estimates of $10.07 by $1.51. Humana had a return on equity of 14.47% and a net margin of 1.42%. The business had revenue of $32.11 billion during the quarter, compared to the consensus estimate of $32 billion. During the same period last year, the firm earned $7.23 earnings per share. The company’s revenue for the quarter was up 8.4% compared to the same quarter last year. Sell-side analysts predict that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be issued a $0.885 dividend. The ex-dividend date of this dividend is Friday, June 27th. This represents a $3.54 dividend on an annualized basis and a yield of 1.54%. Humana’s dividend payout ratio is currently 25.04%.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on HUM. Raymond James Financial upgraded Humana from a “market perform” rating to an “outperform” rating and set a $315.00 price target for the company in a report on Thursday, May 1st. Guggenheim began coverage on Humana in a report on Wednesday, April 9th. They issued a “buy” rating and a $326.00 price target for the company. Truist Financial set a $280.00 price target on Humana and gave the stock a “hold” rating in a report on Tuesday, June 17th. Cantor Fitzgerald restated a “neutral” rating and issued a $290.00 price target on shares of Humana in a report on Thursday, May 1st. Finally, Barclays set a $268.00 target price on Humana and gave the company an “equal weight” rating in a research note on Thursday, June 12th. Seventeen equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, Humana currently has an average rating of “Hold” and an average price target of $280.76.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.